ArticleJournal of the Endocrine Society2025
Low Testosterone Among Males in Opioid Agonist Therapy and Its Association With Fatigue and Psychological Distress.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between thyroidea function and opioid agonist therapy: a prospective cohort study from Norway.Journal of the Endocrine Society · 2026Article
- Low Testosterone Among Males in Opioid Agonist Therapy and Its Association With Fatigue and Psychological Distress.Journal of the Endocrine Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Low testosterone levels are often considered an adverse effect of chronic opioid use. However, the prevalence of low testosterone levels and the association between testosterone levels and clinical symptoms among males receiving opioid agonist therapy (OAT) remain unclear. Objective: To biochemically investigate the prevalence of low testosterone levels (free testosterone ≤0.22 nmol/L) and the association between free testosterone levels and symptoms of fatigue, measured using the 3-item Fatigue Severity scale, and psychological distress, measured using the 10-item Hopkins Symptoms Checklist. Design and Setting: Prospective cohort study based on data collected between May 2017 and May 2024 from males receiving OAT recruited from OAT clinics at Haukeland University Hospital, Bergen, Norway. Participants: 295 males aged 23 to 71 years, with a mean OAT duration of 8 years. Results: A total of 236 (80%) of participants had low testosterone levels at baseline, and 108/148 (73%) had low testosterone levels in 2 consecutive measurements. No association was found between free testosterone and fatigue (baseline: coefficient: -1.0, 95% confidence interval: -6.4; 4.5, Δscore/year: 0.8, -5.2; 6.8) or between free testosterone and psychological distress (baseline: 0.4, -0.3; 1.0, Δscore/year: -0.1, -0.3; 0.2). Conclusion: Eighty percent of males receiving OAT had low testosterone levels. However, testosterone levels were not associated with symptoms of fatigue or psychological distress. These findings should be interpreted with caution due to suboptimal power and potential influence of confounding. Further research is warranted to clarify the clinical significance of biochemical threshold values for low testosterone levels and their relationship to specific clinical symptoms in the OAT population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.